年销超六亿的中药注射液又出致死案例

Core Viewpoint - The recent incident involving the use of Siberian Ginseng injection has reignited medical controversies, particularly concerning its safety and the potential for severe allergic reactions leading to fatalities [1][5][6]. Industry Overview - The market for Siberian Ginseng injection is highly concentrated, with only six companies involved in its production, including Ussuri River Pharmaceutical and companies under listed firms such as Zhenbaodao and Zhongguancun [3][4]. - The market size for Siberian Ginseng injection has seen rapid growth, increasing from 186 million yuan in 2019 to 656 million yuan in 2023, with a remarkable year-on-year growth of 133.58% from 2022 to 2023 [3][4]. Sales and Financial Performance - In 2023, Ussuri River Pharmaceutical reported sales of 450 million yuan for Siberian Ginseng injection, while other companies reported significantly lower sales figures, indicating a dominant market position for Ussuri River [4]. - Zhenbaodao achieved a revenue of 2.707 billion yuan in 2024, a decrease of 13.9% year-on-year, while Zhongguancun reported a revenue of 2.532 billion yuan, an increase of 11.22% year-on-year [3]. Regulatory Environment - The use of traditional Chinese medicine injections, including Siberian Ginseng, has faced increasing regulatory scrutiny, with restrictions on their use in lower-tier medical institutions and specific disease applications [7][8]. - Recent changes in the national medical insurance directory have relaxed some restrictions on traditional Chinese medicine injections, allowing for broader use starting January 1, 2024, although Siberian Ginseng injection remains limited to secondary and higher medical institutions [7][8].